Purpose of Study:
Studying inhaled sirolimus in PH-ILD patients
Study Dates:
July 1, 2026 - May 1, 2027
Type of Study:
Pre-Market
Study Design:
Controlled Design
Study Location:
Nationwide
Lead Institution:
Academic and non-academic Pulmonology/Cardiology groups
Sponsors:
Orphai Therapeutics
Contact:
Maile Krumpschmidt, MD
Contact Email: mkrumpschmidt@orphai-therapeutics.com
ClinicalTrails.gov Identifier:
NCT05798923
